Cases/cancer deaths, n |
202/68 |
37/22 |
193/168 |
124/55 |
556/313 |
Sex, cases/cancer deaths, n |
|
|
|
|
|
Men |
0 |
23/15 |
122/105 |
79/35 |
224/155 |
Women |
202/68 |
14/7 |
71/63 |
45/20 |
332/158 |
Age at diagnosis |
|
|
|
|
|
Years, median (range) |
55 (34–75) |
58 (32–75) |
59 (39–82) |
57 (39–79) |
57 (32–82) |
Time between prediagnostic serum sampling and diagnosis |
|
|
|
|
|
Years, median (range) |
11.7 (1.1–28.9) |
13.5 (3.0–22.1) |
17.7 (2.3–34.4) |
15.2 (2.9–31.8) |
14.4 (1.1–34.4) |
Prediagnostic 25-OHD, nmol/L, median (range) |
62.5 (18.0–119.0) |
61.0 (24.0–129.0) |
64.5 (17.4–132.4) |
64.4 (32.3–142.5) |
63.3 (17.4–142.5) |
1 [<46 nmol/L], mean (n) |
36.3 (44) |
36.0 (7) |
37.7 (41) |
40.1 (22) |
37.5 (114) |
2 [46–61 nmol/L], mean (n) |
53.9 (56) |
55.1 (14) |
54.7 (50) |
54.7 (34) |
54.5 (154) |
3 [62–81 nmol/L], mean (n) |
71.4 (65) |
72.6 (10) |
71.9 (58) |
70.5 (35) |
71.4 (168) |
4 [≥82 nmol/L], mean (n) |
94.3 (37) |
101.3 (6) |
97.4 (44) |
97.7 (33) |
96.7 (120) |
Season-standardized prediagnostic 25-OHD nmol/L, median (range) |
61.4 (20.9–139.5) |
60.7 (25.9–111.6) |
64.0 (18.2–151.7) |
66.5 (34.8–128.7) |
63.2 (18.2–151–7) |
Diagnostic 25-OHD, nmol/L, median (range) |
72.0 (13.0–177.0) |
62.0 (24.0–124.0) |
55.0 (15.0–184.0) |
59.5 (16.0–185.0) |
62.5 (13.0–185.0) |
1 [<46 nmol/L], mean (n) |
34.7 (29) |
38.0 (10) |
34.8 (60) |
35.9 (39) |
35.3 (138) |
2 [46–61 nmol/L], mean (n) |
54.0 (47) |
50.0 (8) |
52.7 (55) |
54.1(26) |
53.3 (136) |
3 [62–81 nmol/L], mean (n) |
71.5 (48) |
71.8 (13) |
71.4 (40) |
70.2 (33) |
71.2 (134) |
4 [≥82 nmol/L], mean (n) |
99.6 (78) |
97.2 (6) |
98.1 (38) |
103.6 (26) |
99.8 (148) |
Season-standardized diagnostic 25-OHD nmol/L, median (range) |
74.2 (13.6–151.9) |
63.9 (26.9–157.6) |
56.6 (15.7–152.7) |
59.3 (16.8–180.6) |
63.5 (13.6–180.6) |